GILD: Gilead Sciences, Inc. - Summary | Jitta

Gilead Sciences, Inc.

NASDAQ:GILD

Price
$62.95
Loss Chance
42.4%
5.00JITTA SCORE
29.78%Below Jitta Line
Jitta Ranking
27 / 811
534 / 4,749
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (5)
Recent Business Performance (45)
Financial Strength (70)
Return to Shareholders (95)
Competitive Advantage (65)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Return on EquityConsistently High
Share RepurchaseEvery Year
CapExVery Low
Revenue and EarningRevenue decline from 2015-2018
Operating MarginDeclined
Key Stats
Jitta Score
Jitta Line
5.00
29.78%
1.76
0.93%
2.38
0.68%
Biotechnology
4.30
34.34%
6.35
25.01%
0.95
100.00%
COMPANY DESCRIPTION
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.